Healthcare Solutions in Emerging Markets

Lupin’s purpose to catalyze treatments that transform hope into healing, finds strong expression in the work it does across emerging markets in Africa, Asia and Latin America.

Emerging pharma markets are growing at an immense pace due to rising healthcare needs, supportive policies, and an expanding middle-class population. However, widespread access to high-quality, effective medicines remains a challenge in these markets.

Lupin’s strategy of expanding access, enhancing impact and fostering resilience with a foundation in excellence and patient-centric care has led these markets to contribute effectively to Lupin’s global sales, reflecting an on-growing stronghold Lupin has through localized offerings and public health partnerships.

MARKETS

Our businesses across emerging markets, including South Africa, Brazil, Mexico, and the Philippines are integral to our global expansion and influencing patient care. These dynamic markets demand affordable, effective, and high-quality treatments. The focus on generic drug manufacturing to create high accessibility at lower costs reflects volume growth, market-specific strategies, and efficient cost structures.

South Africa

South Africa is one of Lupin's most promising emerging markets, a nation where access to affordable, accessible and quality healthcare remains imperative. The region hosts a diverse portfolio with a plethora of therapy areas, including cardiac care, diabetes, CNS, and women’s health, to name a few.

Lupin’s subsidiary, Pharma Dynamics, is a leading provider of generic medication and the largest supplier of heart medication in South Africa. Today, we host a broad portfolio of products that consistently rank among the top in key therapy areas, while our OTC franchise also demonstrates strong market leadership.

Through plans of active expansion in the coming years, South Africa market is one of the canvases where Lupin’s purpose comes alive.

Know more about South Africa market

Brazil

MedQuímica, our subsidiary in Brazil, develops various solid and liquid medications that include OTC, branded generics, hospital medications, and food supplements. Certified by the Brazilian Health Regulatory Agency, MedQuímica has penetrated the Brazilian pharma market and impacted millions of lives through affordable and highly accessible medicines.

Know more about Brazil market

Mexico

Lupin’s subsidiary Laboratories Grin continues to play a vital role in Mexico, showcasing steady growth, making it one of the top pharma companies in Latin America.

Laboratories Grin is leading the way with its strong presence in the Ophthalmology segment.

As we move forward, Laboratories Grin will reinforce its position in the Ophthalmology segment by expanding into adjacent therapies to reach a broader audience. We aim to deepen our innovative capabilities and local insights to offer accessible care to our patients.

Know more about Mexico market

Philippines

Our subsidiary in the Philippines, Multicare Pharmaceuticals, aims to diversify our portfolio, scale operations, and elevate healthcare standards. We are the leading Indian pharmaceutical company in the Philippines and rank among the top in the branded generics segment, covering various therapeutic areas such as rheumatology, women's health, oncology, neuroscience, diabetes, gastroenterology, respiratory conditions, and tuberculosis.

Multicare Pharmaceuticals not only believes in developing high-quality medication but also demonstrates holistic patient care through its patient access programs, offering free consultation to 15,000+ patients.

Know more about the Philippines market

India

India’s pharmaceutical landscape is undergoing rapid transformation, fueled by demographic shifts, an increase in chronic and lifestyle-related diseases, and growing expectations for better healthcare solutions. This momentum has intensified the focus on patient-centric approaches, localized innovation, and integrated care, making India one of the most dynamic and promising pharma markets globally.

Within this environment, Lupin’s India Region Formulations (IRF) business has emerged as a strong growth engine, consistently outperforming the market. Ranked 8th in the Indian Pharmaceutical Market, IRF is driven by its core therapies—cardiac, respiratory, anti-diabetic, and gastrointestinal.

Know more about India market

Middle East and North Africa (MENA)

MENA pharmaceutical market is experiencing significant growth, driven by factors such as the increasing prevalence of chronic diseases, rising healthcare expenditures, government initiatives aimed at localizing manufacturing and improving healthcare access. MENA generic pharmaceutical market is dominated by local companies while Indian companies have a low share. Key opportunities for pharmaceutical companies in the MENA region include government investment, market expansion, digital transformation and innovation and research. These factors position MENA as a promising market for growth from a future perspective.

Lupin is entering into strategic collaborations and partnerships with leading local companies in the MENA region. Lupin, with its wide product portfolio and R&D capabilities, is committed to providing affordable access to high quality medicines to patients across the MENA region.

GLOBAL INSTITUTIONAL BUSINESS(GIB)

Lupin is dedicated to patient communities, and this is reflected through specific programs that aim at battling disease burden globally. Through our Global Institutional Business (GIB), we work closely with public health institutions and regulatory bodies across more than 50 countries in Africa, Latin America, CIS (Commonwealth of Independent States) and Asia.

For decades, Lupin has delivered affordable and accessible healthcare to underserved communities, with a sharp focus on fighting TB and HIV.

Today, Lupin has forayed into being a one-stop shop for all relevant first-line, second- line and preventive TB and HIV medications.

Lupin is one of the world’s largest suppliers of first-line anti-TB medicines. Our proven capability in fermentation technology enables the manufacture of Rifa-based products including Rifampicin, Rifapentine, and Rifabutin.

Our regulatory reach across the globe has ensured in-country registrations of anti-TB and HIV drugs across all high-burden countries in Africa, Asia, LATAM and CIS.

A key milestone was recently achieved with Lupin becoming the first company globally to receive WHO approval for Rifapentine 150 mg dispersible tablets, a pediatric formulation for TB prevention.

We have large installed production capacities to meet the global requirements of anti-TB and HIV drugs. Our API and formulation facilities have approvals from various regulatory authorities across the globe, including WHOPQ, USFDA, CDSCO, SAHPRA, etc.

With its scale, robust capabilities, and a commitment to help those who need care the most, Lupin, through GIB, reaffirms its commitment to a TB-free world, while continuing to address other high-burden diseases in underserved communities.

Lupin stands committed to being a strong and reliable company in the domain of tuberculosis and HIV.